MS vs TGTX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MS and TGTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MS and TGTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Morgan Stanley is a global financial services firm founded in 1935 and headquartered in New York City, with offices in 42 countries and more than 80,000 employees. It operates through three segments: Institutional Securities (investment banking, equity and fixed-income trading, prime brokerage, and research), Wealth Management (financial-advisor-led brokerage, investment advisory, lending, and banking services for individuals and families), and Investment Management (equity, fixed income, alternatives, and liquidity strategies for institutions and intermediaries). The firm earns revenue through advisory and underwriting fees, trading gains, and, increasingly, recurring asset-based fees tied to the value of client assets across its wealth and investment management platforms. The current Morgan Stanley took its modern shape through the 1997 merger with Dean Witter Discover and a string of subsequent acquisitions, most notably E*TRADE (2020) and Eaton Vance (2021), which dramatically expanded its self-directed brokerage and asset management capabilities. Ted Pick became Chairman and CEO at the start of 2024, succeeding James Gorman, who had led the firm since 2010 and orchestrated its transformation toward fee-based businesses. Under Pick, the integrated-firm strategy emphasizes cross-selling across all three segments and driving client assets toward fee-based relationships to generate more predictable earnings.

Full MS guide

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company whose business is dominated by a single approved product: BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis (MS). BRIUMVI launched commercially in the United States in early 2023 and has become one of the faster-growing MS therapies, competing against much larger anti-CD20 rivals. Because the company's revenue is concentrated in this one drug, its results and stock track BRIUMVI's prescription growth, pricing, and market-share gains far more than any broad pipeline.

Full TGTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MS drivers: Wealth management as a recurring-revenue engine; Capital-markets cycle recovery.
• TGTX drivers: BRIUMVI revenue growth and share gains; Swing to sustained profitability.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: A simultaneous downturn in asset prices and capital-markets activity would pressure both the fee-based wealth revenues and the transaction-dependent Institutional Securities segment at the same time, which is the scenario that most concerns long-term holders. For TGTX, the dominant risk is single-product concentration: with essentially all revenue from BRIUMVI, any slowdown in prescription growth, a pricing or reimbursement setback, or an unexpected safety signal would hit the whole company, unlike a diversified pharma.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MS if you believe its drivers more; TGTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MS and TGTX guides.

MS. Morgan Stanley's trailing P/E of roughly 19 to 20 times sits modestly above its own 5-year historical average of around 14 to 15 times, reflecting the market's recognition of the firm's successful shift toward more durable, fee-based earnings. The ROTCE of 21.6% for full-year 2025 demonstrates that the integrated-firm model is generating returns well above most peers' cost of equity, though sustaining that level depends on continued strength in both capital markets and wealth inflows. At a forward P/E of approximately 17.6 times, the stock is not priced as a deep-value name, meaning expectations for continued earnings growth are already embedded in the current price.

TGTX. These figures are approximate and tied to the asOf date; verify live numbers before acting. As a fast-growing, single-product biotech, TG Therapeutics is valued mostly on the expected future trajectory of one drug, so traditional earnings multiples matter less than the pace and durability of BRIUMVI's growth. Guidance has been raised repeatedly, but forward estimates are inherently uncertain and clinical or competitive setbacks could change the picture quickly.

Headline figures (approximate, 2026-06-27): MS shows revenue (full year 2025) ~$70.6 billion, net income (full year 2025) ~$13.4 billion (approx., based on ~$10.21 EPS on ~1.58B diluted shares), eps (ttm) ~$11.04, p/e ratio (ttm) ~19-20x; TGTX shows revenue (ttm) Growing rapidly; BRIUMVI U.S. sales were ~$594M in FY2025 (up ~92% year over year), with 2026 guidance raised to ~$885-900M, profitability Turned profitable in 2025 with several consecutive profitable quarters; a notable inflection for a single-product biotech, revenue concentration Effectively all revenue from one drug, BRIUMVI, in multiple sclerosis, valuation multiple Trades as a growth biotech; multiples reflect expected future BRIUMVI growth rather than current earnings, so they can look elevated.

MS and TGTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MS and TGTX exposure against your real portfolio. It is not an investment adviser.